Skip to ContentSkip to Navigation
About us Medical Sciences Research Pediatrics
University Medical Center Groningen

New key publication:Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice.

06 January 2017
TICE-FXR
TICE-FXR

Intestinal Farnesoid X Receptor Controls Transintestinal Cholesterol Excretion in Mice

PX20606 (PX) activates FXR in the intestine, leading to the production of FGF15/19 which, in turn, causes a shift in bile salt pool composition towards more hydrophilic bile salts. At the level of the enterocyte, excretion of cholesterol from the cell into the intestinal lumen is induced in a manner that largely depends on the activity of ABCG5/G8. As the amount of ABCG5/G8 protein on the brush border membrane remains unchanged upon PX treatment, the transport activity must be increased. Hydrophilic bile salts may facilitate increased export of cholesterol from enterocytes by ABCG5/G8. When re-uptake of exported cholesterol is blocked by addition of ezetimibe to the diet of PX-treated mice, this leads to even further increased cholesterol disposal from the body.

More:

Last modified:28 March 2017 10.12 a.m.

More news

  • 14 February 2023

    Lift to the inclusive workplace

    There is plenty of work, and yet people with a disability are still often sidelined. One plus one is two, or so you’d think: this is the perfect time to help this group of workers find a job. The intention is there, also within the University, but...

  • 15 December 2022

    Groningen contributes to major research initiative into energy-efficient information technology

    The Dutch science funding agency NWO recently awarded a large research project into new concepts for energy-efficient information technology of no less than ten million euros

  • 05 December 2022

    Frans J. Sijtsma new Director Agricola School

    On the recommendation of the Board of the University of Groningen, Dr Frans J. Sijtsma has been appointed as academic director of the Rudolf Agricola School for Sustainable Development with effect from 1 February 2023. This concerns a 0.5 FTE...